Table 1.

Medication assignment, demographic and baseline psychiatric variables for bipolar smokers (n=5).

	Participant 1	Participant 2	Participant 3	Participant 4	Participant 5	Full Sample (n=5)
Study Medication Assignment	BUP	BUP	PLA	PLA	PLA	--
Number of study weeks completed (max. 10)	10	4	9	10	10	8.6 ± 2.6
Endpoint abstinence	Quit	Not Quit	Not Quit	Not Quit	Not Quit	1 Quit/4 Not Quit
Gender	Female	Male	Male	Female	Female	2M/3F
Race	Caucasian	Caucasian	Caucasian	Caucasian	Caucasian	5 C
Age (years)	54	60	61	47	64	57.2 ± 6.8
Baseline CPD	20	20	35.29	13.29	12.14	20.1 ± 9.2
Endpoint CPD	0	1.42*	35**	13.57	4.29	10.9 ± 14.5
Baseline CO level (ppm)	25	16	26	13	10	17.4 ± 8.1
Endpoint CO level (ppm)	0	20*	29**	10	7	13.2 ± 11.4
Mood Stabilizer	Lithium 900 mg/day	Lithium 600 mg/day	Valproate Sodium 1000 mg/day	Lithium 600 mg/day	Lithium 600 mg/day	4 Lithium/1 Valproate
FTND	7	7	10	4	4	6.4 ± 2.5
Age of Smoking Onset	13	18	12	15	15	14.6 ± 2.3
Duration of Smoking (years)	41	42	49	25	49	41.2 ± 9.8
Pack-years	59	42	86	19	78	56.8 ± 27.2
Number of Lifetime Quit Attempts	5	4	6	2	5	4.4 ± 1.5
Contemplation Ladder	8	5	6	6	8	6.6 ± 1.3
BDI	0	6	20	12	12	10.0 ± 7.5
HDRS 17 item	6	2	9	6	2	5.0 ± 3.0
HDRS 21 item	8	2	12	9	2	6.6 ± 4.5
Young Mania Rating Scale	4.5	5.5	4.5	3.0	0.5	3.6 ± 2.0

Key: BUP, bupropion; PLA, placebo; M, male; F, female; C, Caucasian; CPD, cigarettes per day; CO, carbon monoxide; FTND, Fagerström Test of Nicotine Dependence; BDI, Beck Depression Inventory; HDRS, Hamilton Depression Rating Scale.

^*CPD and CO from last week of participation in the study (Week 4)

^**CPD and CO from last week of participation in the study (Week 9)